Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Floor J. Backes, MD
Published: Monday, Nov 04, 2019



Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses the next steps regarding a phase I trial (NCT02788708) investigating lenvatinib (Lenvima) and weekly paclitaxel in women with recurrent endometrial cancer. 
 
According to data presented at the 2019 Society of Gynecologic Oncology Annual Meeting, investigators reported an objective response rate of 50%in this patient population, with a median progression-free survival of 12.8 months. 
 
The next step is to evaluate the combination with pembrolizumab (Keytruda) in a larger trial, says Backes. Notably, a basket trial of patients with endometrial and ovarian cancer could make the path toward regulatory approval easier.
SELECTED
LANGUAGE


Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses the next steps regarding a phase I trial (NCT02788708) investigating lenvatinib (Lenvima) and weekly paclitaxel in women with recurrent endometrial cancer. 
 
According to data presented at the 2019 Society of Gynecologic Oncology Annual Meeting, investigators reported an objective response rate of 50%in this patient population, with a median progression-free survival of 12.8 months. 
 
The next step is to evaluate the combination with pembrolizumab (Keytruda) in a larger trial, says Backes. Notably, a basket trial of patients with endometrial and ovarian cancer could make the path toward regulatory approval easier.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x